MLAB vs RGEN vs BRKR vs TMO vs DHR

For growth investors, Repligen Corporation (RGEN) is the stronger pick with 16.

4% revenue growth year-over-year, versus 2. 1% for Bruker Corporation (BRKR). Thermo Fisher Scientific Inc. (TMO) offers the better valuation at 26. 8x trailing P/E (19. 1x forward), making it the more compelling value choice. Analysts rate Repligen Corporation (RGEN) a "Buy" — based on 23 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Thermo Fisher Scientific Inc.

(TMO) is the cheapest at 26. 8x versus Repligen Corporation at 147. 0x. On forward P/E, Mesa Laboratories, Inc. is actually cheaper at 11. 7x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Thermo Fisher Scientific Inc. wins at 9. 05x versus Danaher Corporation's 34. 35x.

Over the past 5 years, Thermo Fisher Scientific Inc.

(TMO) delivered a total return of +2. 8%, compared to -56. 5% for Mesa Laboratories, Inc. (MLAB). Over 10 years, the gap is even starker: RGEN returned +369. 1% versus MLAB's +4. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Danaher Corporation (DHR) is the lower-risk stock at 0.

94β versus Mesa Laboratories, Inc. 's 1. 78β — meaning MLAB is approximately 90% more volatile than DHR relative to the S&P 500. On balance sheet safety, Repligen Corporation (RGEN) carries a lower debt/equity ratio of 33% versus 114% for Mesa Laboratories, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Repligen Corporation (RGEN) is pulling ahead at 16.

4% versus 2. 1% for Bruker Corporation (BRKR). On earnings-per-share growth, the picture is similar: Repligen Corporation grew EPS 287. 0% year-over-year, compared to -119. 7% for Bruker Corporation. Over a 3-year CAGR, BRKR leads at 10. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Thermo Fisher Scientific Inc.

(TMO) is the more profitable company, earning 15. 1% net margin versus -0. 8% for Mesa Laboratories, Inc. — meaning it keeps 15. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: DHR leads at 20. 9% versus 6. 8% for MLAB. At the gross margin level — before operating expenses — MLAB leads at 62. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Thermo Fisher Scientific Inc. (TMO) is the more undervalued stock at a PEG of 9. 05x versus Danaher Corporation's 34. 35x. Both stocks trade at elevated growth-adjusted valuations, so expected growth needs to materialise. On forward earnings alone, Mesa Laboratories, Inc. (MLAB) trades at 11. 7x forward P/E versus 64. 3x for Repligen Corporation — 52. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for DHR: 40. 6% to $247. 00.

In this comparison, DHR (0.

7% yield), MLAB (0. 6% yield), TMO (0. 4% yield), BRKR (0. 3% yield) pay a dividend. RGEN does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Danaher Corporation (DHR) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

94), 0. 7% yield, +219. 3% 10Y return). Bruker Corporation (BRKR) carries a higher beta of 1. 59 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (DHR: +219. 3%, BRKR: +67. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (MLAB (Technology) and RGEN (Healthcare) and BRKR (Healthcare) and TMO (Healthcare) and DHR (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: MLAB is a small-cap quality compounder stock; RGEN is a small-cap high-growth stock; BRKR is a small-cap quality compounder stock; TMO is a mid-cap quality compounder stock; DHR is a mid-cap quality compounder stock. MLAB, DHR pay a dividend while RGEN, BRKR, TMO do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.